|
US6566500B1
(en)
|
1999-03-30 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinaceous compounds
|
|
EP1935431A3
(fr)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Traitements anti-cancéreux utilisant une combinaison d'anticorps contre le HER2 et l'interleukine-2
|
|
US6689353B1
(en)
*
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
US7723102B2
(en)
*
|
2000-09-28 |
2010-05-25 |
Bayer Corporation |
Enhanced transfection system
|
|
MY139948A
(en)
*
|
2000-09-28 |
2009-11-30 |
Bayer Corp |
Enhanced transfection system
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
PT1454138E
(pt)
*
|
2001-12-04 |
2012-03-28 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
WO2005007121A2
(fr)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Polypeptides de l'interleukine-2(il-2) mutante
|
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
ES2359473T3
(es)
*
|
2003-07-21 |
2011-05-23 |
Transgene S.A. |
Citoquinas multifuncionales.
|
|
EP1694360B1
(fr)
|
2003-11-04 |
2010-08-04 |
Novartis Vaccines and Diagnostics, Inc. |
Utilisation d'anticorps antagonistes anti-cd40 pour le traitement de maladies autoimmunes et inflammatoires et le rejet d'organes transplantes
|
|
JP5744369B2
(ja)
*
|
2004-02-27 |
2015-07-08 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
|
|
RU2006135112A
(ru)
*
|
2004-03-05 |
2008-04-10 |
Чирон Корпорейшн (Us) |
Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
|
|
WO2009061853A2
(fr)
*
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Polypeptides d'interleukine-2 (il-2) mutants
|
|
CN101244261B
(zh)
*
|
2008-03-10 |
2010-09-15 |
山东大学 |
一种含未复性重组蛋白的生物制剂及其制备方法与应用
|
|
DE102008023820A1
(de)
*
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
CA2749539C
(fr)
|
2009-01-21 |
2022-07-19 |
Amgen Inc. |
Compositions et methodes comprenant des mutants d'interleukine-2 destinees au traitement de maladies inflammatoires et auto-immunes
|
|
CN102101885B
(zh)
*
|
2010-09-01 |
2013-06-05 |
南京发士达生物科技有限公司 |
低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
|
|
PT2637694T
(pt)
|
2010-11-12 |
2021-05-05 |
Nektar Therapeutics |
Conjugados de uma fração de il-2 e um polímero
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
|
DK3489255T3
(da)
|
2011-02-10 |
2021-08-23 |
Roche Glycart Ag |
Muterede interleukin-2-polypeptider
|
|
WO2012119093A1
(fr)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonistes et antagonistes de l'interleukine-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
EP3049445A4
(fr)
|
2013-09-24 |
2017-10-25 |
Medicenna Therapeutics, Inc. |
Protéines hybrides de l'interleukine-2 et leurs utilisations
|
|
MA39250B1
(fr)
|
2014-02-06 |
2018-09-28 |
Hoffmann La Roche |
Protéines hybrides de l'interleukine-2 et leurs utilisations
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CA2946398A1
(fr)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonistes, agonistes et antagonistes partiels de l'interleukine-2
|
|
SG11201700629TA
(en)
*
|
2014-08-11 |
2017-02-27 |
Delinia Inc |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2017201432A2
(fr)
*
|
2016-05-19 |
2017-11-23 |
Jounaidi Youssef |
Interleukine-2 liée à son récepteur il-2rbêta, plate-forme pour améliorer l'activité des cellules tueuses naturelles et des lymphocytes t régulateurs
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
EP3475413B1
(fr)
|
2016-06-22 |
2024-02-14 |
David Klatzmann |
Lymphocytes t génétiquement modifiés
|
|
WO2018083248A1
(fr)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
|
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
|
BR112019011799B1
(pt)
*
|
2016-12-13 |
2021-12-21 |
Delinia, Inc |
Proteína de fusão, proteína dimérica e composição farmacêutica
|
|
CA3056630A1
(fr)
|
2017-03-15 |
2018-09-20 |
Pandion Therapeutics, Inc. |
Immunotolerance ciblee
|
|
CA3064435A1
(fr)
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Immunotolerance ciblee
|
|
EP3630162A1
(fr)
*
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Protéines greffées anticorps-cytokine et méthodes d'utilisation
|
|
JOP20190271A1
(ar)
*
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
US11542312B2
(en)
|
2017-06-19 |
2023-01-03 |
Medicenna Therapeutics, Inc. |
IL-2 superagonists in combination with anti-PD-1 antibodies
|
|
US20200181220A1
(en)
*
|
2017-08-03 |
2020-06-11 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
|
US20200299349A1
(en)
*
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
JP2021506291A
(ja)
|
2017-12-19 |
2021-02-22 |
ゼンコア インコーポレイテッド |
改変されたｉｌ−２ ｆｃ融合タンパク質
|
|
EP3752178A1
(fr)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Utilisation de l'interleukine 2 pour traiter le syndrome de sjögren
|
|
MX2020009975A
(es)
|
2018-03-28 |
2020-10-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
|
|
AU2019246389A1
(en)
|
2018-03-28 |
2020-08-27 |
Ascendis Pharma Oncology Division A/S |
IL-2 conjugates
|
|
WO2020007937A1
(fr)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
|
|
CA3106858A1
(fr)
*
|
2018-07-24 |
2020-01-30 |
Biontech Rna Pharmaceuticals Gmbh |
Agonistes d'il2
|
|
WO2020035482A1
(fr)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
|
|
MX2020007072A
(es)
*
|
2018-09-17 |
2020-11-11 |
Gi Innovation Inc |
Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma.
|
|
TW202034945A
(zh)
|
2018-12-21 |
2020-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種人白細胞介素２變體或其衍生物
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
TW202115105A
(zh)
*
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Ｒｎａ製藥有限公司 |
Ｉｌ２激動劑
|
|
MX2022001866A
(es)
*
|
2019-08-13 |
2022-03-11 |
Amgen Inc |
Muteinas de interleucina-2 para la expansion de celulas t reguladoras.
|
|
JP2023505590A
(ja)
|
2019-12-12 |
2023-02-09 |
イルトゥー・ファルマ |
インターロイキン２キメラ構築物
|
|
CA3162705A1
(fr)
|
2019-12-17 |
2021-06-24 |
Amgen Inc. |
Double agoniste de l'interleukine-2/ recepteur du tnf destine a etre utilise en therapie
|
|
US11633488B2
(en)
|
2020-01-10 |
2023-04-25 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
KR102653906B1
(ko)
|
2020-01-14 |
2024-04-03 |
신테카인, 인크. |
편향된 il2 뮤테인 방법 및 조성물
|
|
KR20220155316A
(ko)
|
2020-03-19 |
2022-11-22 |
이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 |
인터루킨-2 돌연변이 및 이의 용도
|
|
AR121713A1
(es)
|
2020-03-31 |
2022-06-29 |
Hanmi Pharm Ind Co Ltd |
Nuevos análogos de il-2 inmunoestimulantes
|
|
EP4161956A1
(fr)
|
2020-06-03 |
2023-04-12 |
Ascendis Pharma Oncology Division A/S |
Séquences d'il-2 et leurs utilisations
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
KR20230097094A
(ko)
|
2020-10-29 |
2023-06-30 |
브리스톨-마이어스 스큅 컴퍼니 |
질환의 치료를 위한 융합 단백질
|
|
CN113308477A
(zh)
*
|
2021-04-08 |
2021-08-27 |
华南农业大学 |
一种鸭il-2基因真核表达重组质粒及其制备方法
|
|
TW202320862A
(zh)
|
2021-09-22 |
2023-06-01 |
大陸商信達生物製藥（蘇州）有限公司 |
介白素２突變體以及其融合蛋白
|
|
WO2023057588A1
(fr)
|
2021-10-06 |
2023-04-13 |
Iltoo Pharma |
Constructions chimériques d'interleukine 2 ont une spécificité de ciblage vis-à-vis des tissus enflammés
|
|
CN114875069B
(zh)
*
|
2022-04-22 |
2023-09-15 |
四川大学 |
基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
|
|
WO2023245097A2
(fr)
*
|
2022-06-16 |
2023-12-21 |
Cephalon Llc |
Immunoconjugués anticorps anti-pd1-il2 atténuée et leurs utilisations
|
|
WO2024056154A1
(fr)
|
2022-09-12 |
2024-03-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interleukine-2 pour le traitement des troubles du spectre autistique
|
|
FR3140287A1
(fr)
|
2022-10-03 |
2024-04-05 |
Arkema France |
Procede de granulation de composes azoiques et granules obtenus
|